Opendata, web and dolomites

SECRETE-HF SIGNED

SECRETED FACTORS IN CARDIAC REMODELING PROVOKE TUMORIGENESIS AND END ORGAN DAMAGE IN HEART FAILURE

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "SECRETE-HF" data sheet

The following table provides information about the project.

Coordinator
ACADEMISCH ZIEKENHUIS GRONINGEN 

Organization address
address: HANZEPLEIN 1
city: GRONINGEN
postcode: 9713 GZ
website: www.umcg.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 1˙999˙861 €
 EC max contribution 1˙999˙861 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-COG
 Funding Scheme ERC-COG
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2024-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ACADEMISCH ZIEKENHUIS GRONINGEN NL (GRONINGEN) coordinator 1˙999˙861.00

Map

 Project objective

The objective of SECRETE-HF is to demonstrate the effects of secreted factors from failing hearts to explain the etiology of multimorbidity in heart failure (HF). The project focuses on two co-morbid patterns: 1) the emerging susceptibility of HF patients for incident cancer, 2) the more established co-morbid conditions of renal, liver and pulmonary disease in HF. The rationale is: • HF treatment has improved, yet morbidity and mortality remain high, which can be attributed to co-morbid conditions rather than pump failure alone. • HF treatment is heart-oriented, neglecting the systemic effects that come with HF, and the associated morbidity and mortality. • Using innovative experimental approaches such as organ transplant models, target finding, and deep phenotyping of clinical databases I will dissect HF-derived effects on tumor growth and organ damage. OBJECTIVES 1. To establish the effects of HF, due to different etiologies, using the state-of-the-art heart transplantation murine model with (spontaneous) formation of colon and renal tumors, and phenotype tumor growth, as well as the main HF-affected organs: kidney, liver and lungs. 2. Identification of the cardiac secretome using unbiased approaches. 3. Integrate the results and identify overlapping and diverse factors from different HF forms, and their consequences for tumor growth and kidney/liver/lung remodeling. 4. Validate discoveries in human cohorts with data on incident HF, cancer and organ function. 5. Create clinical algorithms to detect, monitor and act on extra-cardiac disease. WORKPACKAGES WP 1: Create HF, murine heart transplantation models; phenotype tumor growth and organ involvement. WP 2: Explore the proteomic, metabolomic and extracellular vesicle profiles from HF subforms. WP 3: Validate secreted factors in vitro and in vivo. WP 4: Validate human relevance in large population-based cohorts with unique phenotyping. WP 5: Describe added value of novel markers and design clinical

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SECRETE-HF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SECRETE-HF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

SuperH (2019)

Discovery and Characterization of Hydrogen-Based High-Temperature Superconductors

Read More  

OBSERVE (2020)

Overcoming cellular barriers to therapeutic RNA delivery using extracellular vesicles

Read More